Which company's targeted drug is crizotinib, and what is its market price?

Crizotinib (trade name: Xalkori), as a multi-target tyrosine kinase inhibitor againstALK-positive non-small cell lung cancer and other specific cancer types, has attracted much attention due to its remarkable efficacy. The following will provide you with a detailed introduction to the manufacturing company and market price information of crizotinib.

Crizotinib was originally developed by the well-known Pfizer Company and was approved by the US FDA in 2011. Subsequently, the drug also successfully passed the approval of PMDA, EMA and my country's CFDA, thus becoming the first ALK kinase inhibitor to enter the market in China. This benefited from Pfizer's deep accumulation in drug research and development.

With the rise of generic drugs, generic versions of crizotinib have begun to emerge on the market. These generic drugs are launched by multiple pharmaceutical companies and are more affordable, increasing patient choice. At present, countries such as Laos and Bangladesh have performed well in the production of generic drugs, and the quality of their generic crizotinib drugs has been widely recognized by the industry.

In terms of price, after crizotinib was included in the national medical insurance, the price has dropped significantly, reducing the cost pressure on patients. According to the latest news, the price of each box of Pfizer's original crizotinib (250mg*60 tablets) has dropped to more than 10,000 yuan. After medical insurance reimbursement, the actual expenditure of patients has been significantly reduced. The generic version of crizotinib provides a more economical option, with a price range of approximately 1,000 to 4,000 yuan per box, depending on the manufacturer and sales channel.

Although generic drugs are less expensive, you still need to carefully consider the quality of the drug and the reputation of the manufacturer when choosing one. Purchasing quality-assured drugs from formal channels is crucial to treatment effectiveness and patient safety.

At the same time, changing dynamics and increased competition in the global pharmaceutical market may have an impact on the price of crizotinib. Therefore, patients and medical institutions need to keep an eye on market dynamics in order to make timely adjustments according to price changes.

Overall, crizotinib is becoming increasingly important in cancer treatment. When choosing original drugs or generic drugs, drug quality and price should be considered comprehensively to ensure the safety and effectiveness of treatment.